|
Post by sla55 on Apr 24, 2016 6:29:09 GMT -5
|
|
|
Post by peppy on Apr 24, 2016 7:50:05 GMT -5
National Account Executive City Valencia
Develop, manage and maintain relationships with key stakeholders, including PBM's, Managed Care Organizations, Government Sponsored Health Plans, GPOs, Physician Networks, Trade Organizations and Integrated Delivery Networks
May work closely where appropriate with the Market Access pricing team to develop business rationale for contracting for formulary access while focusing on profitability and impact on corporate sales goals
Build payer profiles to assess formulary review and coverage policies, utilization controls and level of influence.
Knowledge of US Payer coverage and reimbursement systems(Private and Government at the federal, state and local levels), regulatory changes as a result of the Affordable Care Act, and pharmaceutical channel dynamics ------------------------------------------------------------
"If you build it they will come." "If you want something done right, you have to do it yourself."
|
|
|
Post by lakon on Apr 24, 2016 15:15:57 GMT -5
It certainly seems as though MNKD has thrown down the gauntlet.
I am curious as to what the most painful exit for the shorts could be...
Success is great, but watching your enemies squirm in agony is priceless. Is that too much? Sorry.
|
|
|
Post by kc on Apr 24, 2016 20:01:56 GMT -5
Reading this Job description indicates to me that MannKind has received help from some larger Pharma in putting together Job descriptions together and they are moving along like a company that has capital backing from some source that has deep pockets larger than just MannKind. I am happy that Management is showing their ability to put together the team necessary to monetize Afrezza. they have some very serious backing from some third party benefactor. My guess is that we will learn about this backing in the next several weeks if not on Tuesday call.
Has MannKind found a financial partner like a Amgen that they will sell some newly minted stock to and that partner will help them independently build their sales and marketing department. Seems that MannKind could then go it alone but have a partner like Amgen buy into the company to insure stability.
Something very good is about to happen. Buckle up for the ride to the Moon.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Apr 24, 2016 20:39:15 GMT -5
Reading this Job description indicates to me that MannKind has received help from some larger Pharma in putting together Job descriptions together and they are moving along like a company that has capital backing from some source that has deep pockets larger than just MannKind. I am happy that Management is showing their ability to put together the team necessary to monetize Afrezza. they have some very serious backing from some third party benefactor. My guess is that we will learn about this backing in the next several weeks if not on Tuesday call.
Has MannKind found a financial partner like a Amgen that they will sell some newly minted stock to and that partner will help them independently build their sales and marketing department. Seems that MannKind could then go it alone but have a partner like Amgen buy into the company to insure stability.
Something very good is about to happen. Buckle up for the ride to the Moon. you started off a wrong foot ..and started making assumptions. 1. Job descriptions are lifted off from the internet 2.Mike , CCO is experienced and being in that role in Amgen knows what positions are needed to build the commercialization team Now based on the above, do you still believe they have a financial partner? there might be a sugar daddy in the back ground , but not on based on 1 and 2.
|
|
|
Post by kc on Apr 25, 2016 7:59:14 GMT -5
You cannot hire staff without the ability to pay for them. They must have a clear picture of what they can do for the next 12 to 24 months in terms of cash and potential revenue coming in To MannKind
|
|
|
Post by sportsrancho on Apr 25, 2016 8:46:10 GMT -5
You cannot hire staff without the ability to pay for them. They must have a clear picture of what they can do for the next 12 to 24 months in terms of cash and potential revenue coming in To MannKind Clearly this is the case! 10 thumbs up kc:-)
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Apr 25, 2016 8:55:19 GMT -5
You cannot hire staff without the ability to pay for them. They must have a clear picture of what they can do for the next 12 to 24 months in terms of cash and potential revenue coming in To MannKind This sounds right and is different from what you stated above .
|
|
|
Post by bradleysbest on Apr 25, 2016 9:01:47 GMT -5
Will be nice if that plan (or parts of the plan) are revealed tomorrow. I like what is happening though.... my optimism is increasing!
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Apr 25, 2016 10:11:03 GMT -5
Will be nice if that plan (or parts of the plan) are revealed tomorrow. I like what is happening though.... my optimism is increasing! MannKind plans to report quarterly earnings on May 9, 2016 and will discuss financial results of the first quarter of 2016 and future financial projections for the remainder of 2016 and beyond at that time.analyst call for the investment community to learn about the company's general commercialization strategy in the US for Afrezza®
investors.mannkindcorp.com/releasedetail.cfm?ReleaseID=964413
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Apr 25, 2016 10:41:12 GMT -5
I see that Rose is listed as the "Host" for the conference call. Wonder if Matt will be there or if he's still recuperating from his eye surgery. Meeting Title: MannKind to Discuss US Commercialization Update for Afrezza
Host(s): Rose Alinaya
Date: Tue, Apr 26, 2016
Time: 2:00 PM PDT
Duration: 1 hourPerhaps. Its a significant surgery given it is the eye and best to let it heal once the right way. Rose was impressive on last call. Composed and articulate. Personally would hope Matt takes it easy and get the eye on the path to a complete recovery. Re: National Account Manager - probably several hires in this role. Much too much work for one person to handle. $ situation: Sanofi, 1-2 international partners with upfront cash or additional shares sold on market depending on amount that comes from the first two. Hopefully no need to sell shares at all but realistically hope is not to do so for another year or so. Can't see getting the full sales team hired, trained and hitting the streets until August - September. Also gives marketing team time to get collateral developed and ready to go along with time for the national account managers to do their thing and start to get payors and other large customers who take time to hear about Afrezza, pricing and get this part of the equation in place. 2H of '16 should be positive.
|
|
|
Post by bradleysbest on Apr 25, 2016 11:19:46 GMT -5
|
|
|
Post by _neil on Apr 25, 2016 18:19:22 GMT -5
I know there are a lot of people who have held on to MNKD way longer than I did and are invested way more than I ever was. Bear with my pessimism but these job postings do no inspire any hope in me. Dilution is imminent and people will take up a job if they are compensated enough with stock options. Even at 50% of today's PPS, if someone is getting a million options with a potential upside several times that amount, it seems like an acceptable risk (at least to me).
I don't think reading too much into the stability of the company just because they are hiring people is wise.
|
|
|
Post by peppy on Apr 25, 2016 20:12:25 GMT -5
I know there are a lot of people who have held on to MNKD way longer than I did and are invested way more than I ever was. Bear with my pessimism but these job postings do no inspire any hope in me. Dilution is imminent and people will take up a job if they are compensated enough with stock options. Even at 50% of today's PPS, if someone is getting a million options with a potential upside several times that amount, it seems like an acceptable risk (at least to me). I don't think reading too much into the stability of the company just because they are hiring people is wise. The stability of the company is "the product, Afrezza." It is fine in many ways. screencast.com/t/4W2uaL19IqtW it works. screencast.com/t/AhnFhHunq MNKD has assets screencast.com/t/MKpIlv432a
Priced correctly, David may be meeting Goliath. screencast.com/t/UStjt3OT Information travels now. #kissmyass
|
|
|
Post by sluggobear on Apr 25, 2016 23:55:18 GMT -5
I agree Neil; it's healthy skepticism and I can't find enough of it these days. There's all kinds of attitudes out there but reasonable, healthy skepticism is in low supply. I try to imagine what my perspective would be if I had sold a year ago (at a little profit even). I know I'd still be rooting for the company and Afrezza but I'd probably be doing it from the cheap seats...I'm not a day trader and this has been one of my riskiest investments ever.
So...the CCO, etc. hiring seems like good news to me. But I like thinking that because I am holding a significant loss potential. I assume they'd be giving it the "old college try" no matter what? Going it alone, they are hiring exactly as they should, whether or not they have any actual 'line of sight' on future cash infusion/funding (beyond the expected dilution). Maybe all hopes are pinned on further dilution and the new hires understand that.
We find out tomorrow whether there are ANY NEW good happenings in the commercialization arena. It may just be what we already know - Castagna, other new hires, Publicis.
I'd be a little less worried if they signed up one OUS distributor and had lined up sales in the Middle East somewhere...
|
|